481 related articles for article (PubMed ID: 19194648)
1. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
[TBL] [Abstract][Full Text] [Related]
2. Pantalone et al.: the risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Bell DS
Acta Diabetol; 2009 Jun; 46(2):155; author reply 157. PubMed ID: 19300899
[No Abstract] [Full Text] [Related]
3. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
4. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
5. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
6. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
[TBL] [Abstract][Full Text] [Related]
7. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
8. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
9. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM
Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
12. Medical therapy for diabetes is associated with increased use of lower endoscopy.
Lewis JD; Capra AM; Achacoso NS; Ferrara A; Levin TR; Quesenberry CP; Habel LA
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1195-202. PubMed ID: 17603822
[TBL] [Abstract][Full Text] [Related]
13. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
[TBL] [Abstract][Full Text] [Related]
14. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones and fractures in men and women.
Dormuth CR; Carney G; Carleton B; Bassett K; Wright JM
Arch Intern Med; 2009 Aug; 169(15):1395-402. PubMed ID: 19667303
[TBL] [Abstract][Full Text] [Related]
16. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
17. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Walker AM; Koro CE; Landon J
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):760-8. PubMed ID: 18383443
[TBL] [Abstract][Full Text] [Related]
18. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
De Flines J; Scheen AJ
Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
Erdmann E; Spanheimer R; Charbonnel B;
J Diabetes; 2010 Sep; 2(3):212-20. PubMed ID: 20923486
[TBL] [Abstract][Full Text] [Related]
20. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]